Welcome back to plenary session. Recently I went to a conference in Kansas City. It was the

Cancer Center Directors conference. It was a conference for cancer center directors. And I was asked

to present about precision oncology. And I gave an overview of all the work we've been doing,

work that is pooled analysis of genome targeted therapies and how many people benefit

from FDA approvals, how many people are benefiting from umbrella and basket studies, and more.

I'm going to make that talk available to you all today on plenary session. As always,

Patreon backers will get access to the slides, and I'll make it available another way, which

is if you follow Vinay Prasad, observations and thoughts, the substack, I'll make the slides

available there too.

So two ways to get the slides if you're interested in this talk.

And on that positive note, here it is, live from Kansas City.

Well, thank you.

Thank you for that introduction.

I see that only the elite remain in this auditorium.

Good, I'm glad to see it.

I'm glad to see.

So I'm going to talk to you about the state of precision oncology.

It's going to be a broad overview.

By way of background, I'm a practicing hemonk doctor. I work at the San Francisco General Hospital and the VA of background I'm a practicing hemonk doctor I work at the San

Francisco General Hospital and the VA but I'm primarily a professor of epidemiology

so what I show you is going to come with the perspective of an epidemiologist

looking very broadly at the field and so hopefully it'll put some of what you

...